Rep. Rick Larsen (D-Wash.) reported a new purchase of McKesson Corporation (MCK) common stock in a Periodic Transaction Report filed with the U.S. House of Representatives. The transaction, dated July 8, 2026, was made by Larsen himself and is valued between $1,001 and $15,000, according to the disclosure.
The trade was executed through the Richard R Larsen IRA, and the filer’s own description characterizes it as ‘Part of advisor-driven quarterly rebalancing.’ STOCK Act filings require members of Congress to disclose trades like this within 45 days, regardless of who initiates them or why, so routine portfolio adjustments made by a financial advisor still show up in the public record. There is no indication in the filing of any wrongdoing, and the disclosure itself is simply compliance with federal transparency law.
A Notable Cross-Signal at McKesson
What makes this filing worth flagging is timing. Within 30 days of Larsen’s purchase, a McKesson company insider, Dominic J. Caruso, filed a sale of MCK shares worth $225,489 on July 22, 2026. Insider filings and congressional disclosures are governed by entirely separate reporting regimes — one under the STOCK Act, the other under SEC Section 16 rules for corporate insiders — so the two transactions are not connected by any shared decision-making process. Still, when a lawmaker’s account and a company insider’s account move in opposite directions on the same stock within a short window, it’s the kind of pattern that readers tracking ‘congress buy’ and ‘congress sell’ signals tend to want visibility into.
Larsen’s purchase falls into the site’s ‘congress buy’ classification, meaning it reflects new or increased exposure to MCK on the lawmaker’s part, at least on paper, through the IRA structure disclosed. McKesson, a major pharmaceutical distributor, is a widely held healthcare name that shows up periodically in both congressional and insider trading disclosures given its size and sector visibility.
For readers who follow this kind of disclosure the way they might track ‘pelosi portfolio’ moves or broader ‘nancy pelosi stock trades 2026’ coverage, the appeal isn’t necessarily about any one trade — it’s about spotting patterns across filings that are otherwise scattered across separate government databases. This McKesson filing, paired with the insider sale later in the month, is exactly the kind of juxtaposition that pattern-watchers flag, even though the filing itself offers no evidence connecting the two events beyond their proximity in time.
As always with these disclosures, the report reflects a legally required filing, not a recommendation or endorsement of any trading strategy.